In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3- sulfate and trans-resveratrol-3-glucuronide

Drug Metabolism and Disposition

Volumn 40, Issue 10, 2012, Pages 1993-2015

  Sharan, Satish ^a   Iwuchukwu, Otito F ^a   Canney, Daniel J ^a   Zimmerman, Cheryl L ^b   Nagar, Swati ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RESVERATROL; RESVERATROL 3 GLUCURONIDE; RESVERATROL 3 SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; GLUCURONIDES; HALF-LIFE; INJECTIONS, INTRA-ARTERIAL; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; STILBENES; SULFATES;

EID: 84866442086     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046417     Document Type: Article

References (38)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr AC-19:716-723.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
3. Berezhkovskiy LM (2004) Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
4. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16:1246-1252. (Pubitemid 46984966)
5. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, et al. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70:9003-9011.
6. Colburn WA (1982) Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs. J Pharm Sci 71:131-133.
7. Colburn WA, Hirom PC, Parker RJ, and Milburn P (1979) A pharmacokinetic model for enterohepatic recirculation in the rat: phenolphthalein, a model drug. Drug Metab Dispos 7:100-102. (Pubitemid 9214604)
8. Colom H, Alfaras I, Maijó M, Juan ME, and Planas JM (2011) Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm Res 28:1606-1621.
9. Dahlström BE and Paalzow LK (1978) Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinet Biopharm 6:505-519.
10. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
11. Davis TM, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, and Barrett PH (2000) Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol 49:223-230. (Pubitemid 30150983)
12. Frederick CB and Obach RS (2010) Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin Pharmacol Ther 87:345-350.
13. Gabrielsson J and Weiner D (2006) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 4th ed, Swedish Pharmaceutical Press, Stockholm.
14. Goldberg DM, Yan J, and Soleas GJ (2003) Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87. (Pubitemid 36126394)
15. Hasselström J and Säwe J (1993) Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24:344-354.
16. Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, and Osterberg RE (2003) Drug metabolites in safety testing. Toxicol Appl Pharmacol 190:91-92.
17. Hoshino J, Park EJ, Kondratyuk TP, Marler L, Pezzuto JM, van Breemen RB, Mo S, Li Y, and Cushman M (2010) Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53:5033-5043.
18. Iwuchukwu OF, Sharan S, Canney DJ, and Nagar S (2012) Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies. J Pharm Biomed Anal 63:1-8.
19. Juan ME, Maijó M, and Planas JM (2010) Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 51:391-398.
20. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, and McCormick DL (2011) Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 68:593-601.
21. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, and Ducharme MP (2002) Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 302:369-373. (Pubitemid 34680460)
22. Meng X, Maliakal P, Lu H, Lee MJ, and Yang CS (2004) Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52:935-942.
23. Moon YJ, Sagawa K, Frederick K, Zhang S, and Morris ME (2006) Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J 8:E433-E442. (Pubitemid 44096604)
24. Ogiso T, Iwaki M, Tanino T, Ikeda K, Paku T, Horibe Y, and Suzuki H (1998) Pharmacokinetics of aniracetam and its metabolites in rats. J Pharm Sci 87:594-598. (Pubitemid 28225624)
25. Ouellet DM and Pollack GM (1995) Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab Dispos 23:478-484.
26. Pang KS (1985) A review of metabolite kinetics. J Pharmacokinet Biopharm 13:633-662.
27. Pang KS (2009) Safety testing of metabolites: expectations and outcomes. Chem Biol Interact 179:45-59.
28. Pang KS, Cherry WF, Terrell JA, and Ulm EH (1984) Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos 12:309-313. (Pubitemid 15120549)
29. Pang KS and Kwan KC (1983) A commentary: methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab Dispos 11:79-84. (Pubitemid 13113885)
30. Pang KS, Morris ME, and Sun H (2008) Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 60:1247-1275.
31. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70:7392-7399.
32. Pearson PG and Wienkers LC (2009) Handbook of Drug Metabolism. Informa Healthcare USA, New York.
33. Prueksaritanont T, Lin JH, and Baillie TA (2006) Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol 217:143-152. (Pubitemid 44780764)
34. Smith DA and Obach RS (2005) Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33:1409-1417. (Pubitemid 41323986)
35. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32:1377-1382. (Pubitemid 39564557)
36. Wenzel E and Somoza V (2005) Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49:472-481. (Pubitemid 40780394)
37. Yates JW and Arundel PA (2008) On the volume of distribution at steady state and its relationship with two-compartmental models. J Pharm Sci 97:111-122.
38. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG, and van Breemen RB (2002) Human, rat, and mouse metabolism of resveratrol. Pharm Res 19:1907-1914. (Pubitemid 36016041)